Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an update.
Paradigm Biopharmaceuticals Limited announced the issuance of 1,708 ordinary fully paid securities to be quoted on the ASX, effective July 22, 2025. This move indicates an expansion of the company’s financial instruments, potentially enhancing its market presence and providing additional resources for its operational and strategic initiatives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for unmet medical needs. The company is primarily engaged in creating treatments for musculoskeletal disorders and rare diseases, with a market focus on innovative drug solutions.
Average Trading Volume: 900,701
Technical Sentiment Signal: Buy
Current Market Cap: A$166.9M
See more data about PAR stock on TipRanks’ Stock Analysis page.